Thus, our data suggest that patients whose ALL involves increased RAG2 or AID-mediated clonal heterogeneity exhibit a more aggressive disease because RAG and AID increase the probability of acquiring high-risk mutations, distinct in the context of CNApos and CNAneg subgroups. This evidence concerns the gene RAG2 and acute lymphoblastic leukemia.